Komori
Financial results presentation2929Pharma Foods International Co.,Ltd.Food

Supplementary Financial Results Explanatory Materials for the Fiscal Year Ending July 2026

Revenue decreased 3.1% year on year, while operating profit increased by ¥264 million due in part to reductions in advertising and promotional expenses, and net income increased significantly. Ordinary profit decreased by ¥113 million.

Worth reading
37Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
264
¥ million
Wording
Definitive
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportFull fiscal year ended July 20265 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥63,223 million-3.1%
Operating profit¥2,632 million+11.2%
Ordinary income¥2,440 million-4.4%
Net income¥1,988 million+439.0%
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • B2B Business
    Change in operating profit-136
  • B2C Business
    Change in operating profit778
  • Biomedical business
    Change in operating profit-460
  • Other and adjustments
    Change in operating profit83
  • Advertising expense reduction¥2,770 million
New initiatives
  • Start of construction of 明治薬品's new plant
  • Investment management that balances growth investment with earnings improvement
  • More efficient management of advertising and promotional expenses
Key KPIsA metric the company considers important as a management benchmark.
  • Cumulative shipments of Neumo Vactory Shampoo156 10,000 units
Segment results
  • B2B Business
    Net Sales¥7,471 million (YoY -8.7%)
    Operating profit¥1,112 million (YoY -10.9%)
  • B2C Business
    Net Sales¥55,368 million (YoY -2.4%)
    Operating profit¥4,481 million (YoY +21.0%)
  • Biomedical business
    Net Sales¥350 million (YoY +5.7%)
    Operating profit¥-838 million
  • Other
    Net Sales¥33 million (YoY +113.3%)
    Operating profit¥-13 million
Financial targets
Equity ratio: 37.5%; D/E ratio: 1.30 (target: Not disclosed)
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings report
Fiscal Period CoveredFull fiscal year ended July 2026
Net Sales¥63,223 million (YoY -3.1%)
Operating profit¥2,632 million (YoY +11.2%)
Ordinary income¥2,440 million (YoY -4.4%)
Net income¥1,988 million (YoY +439.0%)
Segment resultsSegment B2B Business / Net Sales ¥7,471 million (YoY -8.7%) / Operating profit ¥1,112 million (YoY -10.9%), Segment B2C Business / Net Sales ¥55,368 million (YoY -2.4%) / Operating profit ¥4,481 million (YoY +21.0%), Segment Biomedical business / Net Sales ¥350 million (YoY +5.7%) / Operating profit ¥-838 million, Segment Other / Net Sales ¥33 million (YoY +113.3%) / Operating profit ¥-13 million
Breakdown of Factors Affecting the ChangeItem B2B Business / Change in operating profit ¥-136 million, Item B2C Business / Change in operating profit ¥778 million, Item Biomedical business / Change in operating profit ¥-460 million, Item Other and adjustments / Change in operating profit ¥83 million, Item Advertising expense reduction / Amount ¥2,770 million
Key KPIsIndicator name Cumulative shipments of Neumo Vactory Shampoo / Value 156 10,000 units / Year on year against the same period last year Not disclosed
Financial targetsEquity ratio: 37.5%; D/E ratio: 1.30 (target: Not disclosed)
New initiativesStart of construction of 明治薬品's new plant, Investment management that balances growth investment with earnings improvement, More efficient management of advertising and promotional expenses
Items this document does not state (20)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company cited the execution of growth investments, positioning the first half as a period for proactive investment and the second half as a period for converting those investments into earnings, a ¥2.77 billion year-on-year reduction in advertising and promotional expenses, improved profitability in the B2C business, and steady sales of the Neumo series and pharmaceuticals.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Financial Results Explanatory Materials for the Fiscal Year Ending July 2026 | Pharma Foods International Co.,Ltd. (2929) timely disclosure | Komori